richard schlenk
richard schlenk
Zugehörigkeit unbekannt
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Genomic classification and prognosis in acute myeloid leukemia
E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ...
New England Journal of Medicine 374 (23), 2209-2221, 2016
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ...
New England Journal of Medicine 358 (18), 1909-1918, 2008
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia
L Bullinger, K Döhner, E Bair, S Fröhling, RF Schlenk, R Tibshirani, ...
New England Journal of Medicine 350 (16), 1605-1616, 2004
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ...
N engl j Med 369, 111-121, 2013
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, ...
New England Journal of Medicine 377 (5), 454-464, 2017
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations
K Döhner, RF Schlenk, M Habdank, C Scholl, FG Rücker, ...
Blood 106 (12), 3740-3746, 2005
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML …
S Fröhling, RF Schlenk, J Breitruck, A Benner, S Kreitmeier, K Tobis, ...
Blood, The Journal of the American Society of Hematology 100 (13), 4372-4380, 2002
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
H Dohner, K Fischer, M Bentz, K Hansen, A Benner, G Cabot, D Diehl, ...
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
J Koreth, R Schlenk, KJ Kopecky, S Honda, J Sierra, BJ Djulbegovic, ...
Jama 301 (22), 2349-2361, 2009
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 …
P Paschka, RF Schlenk, VI Gaidzik, M Habdank, J Krönke, L Bullinger, ...
Journal of clinical oncology 28 (22), 3636-3643, 2010
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations
S Fröhling, RF Schlenk, I Stolze, J Bihlmayr, A Benner, S Kreitmeier, ...
Journal of Clinical Oncology 22 (4), 624-633, 2004
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ...
Blood 119 (9), 2114-2121, 2012
Individual patient data–based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia …
RF Schlenk, A Benner, J Krauter, T Buchner, C Sauerland, G Ehninger, ...
Journal of Clinical Oncology 22 (18), 3741-3750, 2004
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
J Krönke, RF Schlenk, KO Jensen, F Tschürtz, A Corbacioglu, VI Gaidzik, ...
Journal of Clinical Oncology 29 (19), 2709-2716, 2011
Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal …
K Döhner, K Tobis, R Ulrich, S Fröhling, A Benner, RF Schlenk, ...
Journal of Clinical Oncology 20 (15), 3254-3261, 2002
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra, M Bornhaeuser, ...
Nature reviews Clinical oncology 9 (10), 579, 2012
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further …
E Taskesen, L Bullinger, A Corbacioglu, MA Sanders, CAJ Erpelinck, ...
Blood, The Journal of the American Society of Hematology 117 (8), 2469-2475, 2011
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
S Kayser, K Doehner, J Krauter, CH Koehne, HA Horst, G Held, ...
Blood, The Journal of the American Society of Hematology 117 (7), 2137-2145, 2011
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic …
S Stilgenbauer, T Zenz, D Winkler, A Buehler, RF Schlenk, S Groner, ...
Journal of Clinical Oncology 27 (24), 3994-4001, 2009
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B
S Fröhling, RF Schlenk, S Kayser, M Morhardt, A Benner, K Döhner, ...
Blood 108 (10), 3280-3288, 2006
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20